BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study (video issues)

https://www.youtube.com/watch?v=bmHQZb5OZqE&embeds_referring_euri=https%3A%2F%2Fbeta.demy-colton.com%2F&feature=emb_imp_woyt

BrainStorm Cell Therapeutics (NASDAQ:BCLI) CMO Dr. Ralph Kern sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.